Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» Lundbeck
Lundbeck
Lundbeck gets cold feet, axes schizophrenia drug trial
Pharmaforum
Thu, 08/6/20 - 11:03 pm
Lundbeck
schizophrenia
clinical trials
Lu AF11167
Lilly touts Emgality's ability to reduce migraine patients' overall pain in first look at 'holistic approach'
Fierce Pharma
Wed, 06/17/20 - 09:52 pm
Eli Lilly
migraines
Amgen
Teva Pharmaceutical
Lundbeck
Emgality
Lundbeck plotting up to 160 R&D job cuts as it rebuilds pipeline
Fierce Biotech
Tue, 06/9/20 - 12:22 pm
Lundbeck
R&D
layoffs
Ovid's lead drug shows promising efficacy signal in Fragile X syndrome study, but optimal dosing regimen is unclear for path forward
Endpoints
Fri, 05/8/20 - 10:34 am
Ovid Therapeutics
Takeda
Lundbeck
Fragile X syndrome
clinical trials
Lundbeck adds a Parkinson's flop to its list of setbacks, writing off a $1.1 billion deal on mid-stage failure
Endpoints
Mon, 03/30/20 - 10:47 am
Lundbeck
R&D
Parkinson's Disease
foliglurax
The fourth CGRP migraine drug is here. Time for Lundbeck to prove it's worth $2B
Endpoints
Sat, 02/22/20 - 11:29 pm
Lundbeck
eptinezumab
migraines
CGRPs
Vyepti
Go or no go? Esperion's double whammy and a look to priority reviews
EP Vantage
Thu, 01/30/20 - 10:43 am
FDA
Esperion Therapeutics
Acacia Pharma
Blueprint Medicines
Agile Therapeutics
Lundbeck
Sun Pharma
Biohaven
Durect Corporation
Lundbeck’s digital strategy and how they manage global and local content
Pharmaforum
Tue, 10/15/19 - 10:20 am
Lundbeck
digital strategy
digital pharma
digital marketing
Biopharma M&A: deal-depressed third quarter leaves nowhere to hide
EP Vantage
Tue, 10/8/19 - 10:53 am
M&A
Lundbeck
Alder Biopharmaceuticals
Gilead Sciences
Galapagos
Vertex Pharmaceuticals
Semma
Swedish Orphan Biovitrum
Dova Pharmaceuticals
Novartis
IFM
Alder's migraine drug attracted plenty of dealmakers. The company, not so much
Biopharma Dive
Wed, 09/25/19 - 09:17 am
Alder Biopharmaceuticals
M&A
Lundbeck
Alder won’t solve Lundbeck’s headaches
EP Vantage
Mon, 09/16/19 - 05:12 pm
Lundbeck
M&A
Alder Biopharmaceuticals
migraines
Lundbeck pens $2B Alder takeover to boost brain disease pipeline
Fierce Biotech
Mon, 09/16/19 - 09:23 am
Lundbeck
Alder Biopharmaceuticals
M&A
Lundbeck strikes $250M Abide buyout, bagging Tourette's drug
Fierce Biotech
Mon, 05/6/19 - 10:50 am
Lundbeck
Abide Therapeutics
M&A
Tourette's syndrome
Jazz Pharma, Lundbeck and Alexion Pay $122 Million to Settle Kickback Allegations
BioSpace
Thu, 04/4/19 - 11:02 pm
Jazz Pharma
Lundbeck
Alexion
kickbacks
charity
Lundbeck fund backs a $50M launch round for SNIPR Biome, a new brand of CRISPR Cas biotech
Endpoints
Mon, 03/11/19 - 09:56 am
Lundbeck
Lundbeck Foundation
startups
CRISPR
SNIPR Biome
Lundbeck joins with Elsevier to help manage R&D data
Pharmaforum
Thu, 02/28/19 - 09:47 am
Lundbeck
R&D
Elsevier
Reaxis
Antipsychotic from Lundbeck, Otsuka flops again in PhIII trials — this time in bipolar patients
Endpoints
Thu, 02/14/19 - 05:45 pm
Lundbeck
Otsuka
brexpiprazole
anti-psychotic
schizophrenia
bipolar disorder
FDA Approves First Generic Version of Lundbeck’s Sabril
RAPS.org
Wed, 01/16/19 - 11:54 pm
FDA
Teva Pharmaceutical
Lundbeck
seizures
generics
Sabril
Vigabatrin
Lundbeck Partners with AI Driven Numerate to Tackle Central Nervous System Disorders
CP Wire
Mon, 01/7/19 - 10:14 am
Lundbeck
Numerate
artificial intelligence
CNS
Lundbeck Partners with AI Driven Numerate to Tackle Central Nervous System Disorders
Mon, 01/7/19 - 10:05 am
Lundbeck
Numerate
artificial intelligence
Pages
« first
‹ previous
1
2
3
4
5
6
7
next ›
last »